Precision Medicine in Oncology® | Specialty

Novel Therapeutic Target Identified in Aggressive Thyroid Cancers

November 1st 2014

In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with β-aminopropionitrile fumarate.

Expert Advises on Managing Side Effects of Targeted Lung Cancer Therapies

November 1st 2014

Jyoti D. Patel, MD, provides insight into managing the toxicities associated with molecular therapies used to treat patients with lung cancers.

Afatinib Extends OS by Approximately 1 Year in Subgroup of NSCLC

October 31st 2014

First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.

Dr. Camidge on Inhibiting Initial Activating EGFR Mutations and the T790M Resistance Mutation

October 31st 2014

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

Dr. Gandara Discusses the Future of Clinical Trial Designs

October 30th 2014

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

Treatment Selection in Metastatic Prostate Cancer

October 16th 2014

Convincing Long-Term Survival With Abiraterone in mCRPC

October 16th 2014

Quality of Life and Survival With Abiraterone in CRPC

October 16th 2014

Researchers Discuss Novel Therapies in NSCLC

October 16th 2014

Latest News & Insight: October 16, 2014

October 16th 2014

ASCO Endorses Molecular Testing Guideline for Lung Cancer

October 14th 2014

ASCO has endorsed the CAP/IASLC/AMP guideline on molecular testing for patients with lung cancer, which recommends EGFR and ALK testing for all patients with lung adenocarcinoma or mixed histology with an adenocarcinoma component.

Rini Discusses Variable Impact of Angiogenesis in Solid Tumors

October 13th 2014

Rini, who is a professor at the Cleveland Clinic Lerner College of Medicine in addition to holding several posts at the Case Comprehensive Cancer Center, discussed broad issues in antiangiogenic research in this interview with OncologyLive.

Advancing Prostate Cancer Care

October 12th 2014

The prostate cancer team at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center has recently focused on two primary areas: minimally invasive care and clinical research.

Olaparib in Ovarian Cancer

October 9th 2014

Maurie Markman on Patient-Centered Cancer Care

October 9th 2014

Herbert Irving Comprehensive Cancer Center

October 9th 2014

Latest News & Insight: October 9, 2014

October 9th 2014

2014 ESMO Congress Highlights

October 9th 2014

Dr. Halmos on Detecting Actionable Mutations in Patients With Lung Cancer

October 7th 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, comments on the detection of actionable mutations in patients with lung cancer.

Commercial Tests Offer Guidance in Bladder, Renal, Testicular Cancers

October 7th 2014

While biomarker-based tools designed to guide the diagnosis and treatment of prostate cancer are emerging at an extraordinarily rapid rate, they are not exploding in the same practice-changing way in all genitourinary cancers.